QLGN Rentabilitas reged Qualigen Therapeutics Inc

The implementation of FastPack AI platforms for automated blood analysis impacts the current gross margin, where the figure remains at 0.00. This chart's dynamics are based on a critical dependence on external R&D contractors. The situation is further complicated by a shift in drug development strategy and a capital shortage, creating serious financial threats for Qualigen Therapeutics (QLGN).
Rincian analitis lan laporan data perusahaan Qualigen Therapeutics, Inc. (QLGN)

As a biotech ecosystem in the drug development stage for brain cancer treatments, Qualigen Therapeutics (QLGN) currently has no commercial sales. An analysis of the gross profit to revenue ratio demonstrates the portion of income remaining after covering direct production costs. This indicator measures the fundamental efficiency of the operating model, where any decline signals risks of capital freeze prior to FDA approval.